Beijing SL Pharmaceutical Co., Ltd. (SHE:002038)

Beijing SL Pharmaceutical Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Jan 1, 2023	Jan 1, 2022	Dec 31, 2020
Cash & Equivalents	328.75	411.96	683.83	595.04	827.84	663.48
Short-Term Investments	-	-	785.86	713.36	646.23	605.63
Trading Asset Securities	456.09	480.86	608.56	144.91	162.36	173.81
Cash & Short-Term Investments	784.84	892.81	2,078	1,453	1,636	1,443
Cash Growth	-35.01%	-57.04%	43.00%	-11.19%	13.41%	-24.62%
Accounts Receivable	100.48	105.79	200.57	254.86	357.56	466.08
Other Receivables	15.22	15.65	35.25	31.35	21.6	2.9
Receivables	115.71	121.44	235.82	286.2	379.16	468.98
Inventory	403.25	246.33	144.46	136.82	124.83	112.03
Other Current Assets	1,258	1,228	181.45	121.34	157.31	183.4
Total Current Assets	2,562	2,489	2,640	1,998	2,298	2,207
Property, Plant & Equipment	513.01	514.24	503.34	527.3	604.01	589.16
Long-Term Investments	1,235	1,231	1,182	1,798	1,404	1,251
Other Intangible Assets	713.14	678.58	693.77	526.36	479.46	423.38
Long-Term Deferred Tax Assets	65.84	69.52	-	39.5	27.65	25.35
Long-Term Deferred Charges	481.48	519	451.89	454.42	394.72	291.84
Other Long-Term Assets	494.79	477.35	806.44	532.22	553.25	606.28
Total Assets	6,065	5,979	6,278	5,876	5,760	5,395
Accounts Payable	139.28	122.29	250.76	176.18	191.4	179.93
Accrued Expenses	37.1	42.95	46.93	30.32	31.8	25.23
Short-Term Debt	-	-	-	-	-	5.51
Current Portion of Leases	-	-	-	-	0.25	-
Current Income Taxes Payable	2.57	3.49	0	2.61	4.48	4.28
Current Unearned Revenue	106.39	70.51	15.29	27.87	13.33	10.01
Other Current Liabilities	48.65	50.18	60.34	51.85	83.71	90.02
Total Current Liabilities	333.99	289.41	373.33	288.83	324.96	314.98
Long-Term Leases	-	-	-	-	2.22	-
Long-Term Unearned Revenue	41.17	44	47.04	51.38	56.23	60.97
Long-Term Deferred Tax Liabilities	63.28	64.97	47.36	56.39	50.82	34.15
Total Liabilities	438.44	398.37	467.72	396.6	434.23	410.09
Common Stock	1,027	1,027	1,027	1,027	1,027	1,027
Additional Paid-In Capital	49.62	49.62	49.62	43.85	32.58	17.59
Retained Earnings	4,528	4,482	4,710	4,396	4,265	3,941
Comprehensive Income & Other	13.47	13.47	13.47	0.67	-12.99	-11.68
Total Common Equity	5,618	5,572	5,801	5,468	5,311	4,975
Minority Interest	7.85	8.2	9.42	11.16	14.73	10.13
Shareholders' Equity	5,626	5,581	5,810	5,479	5,326	4,985
Total Liabilities & Equity	6,065	5,979	6,278	5,876	5,760	5,395
Total Debt	-	-	-	-	2.47	5.51
Net Cash (Debt)	784.84	892.81	2,078	1,453	1,634	1,437
Net Cash Growth	-35.01%	-57.04%	43.00%	-11.06%	13.67%	-24.75%
Net Cash Per Share	0.72	0.84	2.04	1.43	1.57	1.42
Filing Date Shares Outstanding	1,149	1,152	1,027	1,027	1,027	1,027
Total Common Shares Outstanding	1,149	1,152	1,027	1,027	1,027	1,027
Working Capital	2,228	2,199	2,267	1,709	1,973	1,892
Book Value Per Share	4.89	4.84	5.65	5.32	5.17	4.84
Tangible Book Value	4,905	4,894	5,107	4,942	4,832	4,551
Tangible Book Value Per Share	4.27	4.25	4.97	4.81	4.70	4.43
Buildings	-	-	437.22	430.73	452.32	457.05
Machinery	-	-	458.48	435.39	415.76	388.59
Construction In Progress	-	-	56.97	64.75	99.87	67.7

Updated Oct 25, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.